radiotherapy

Gimeracil (Gimestat) is a competitive, reversible inhibitor of dihydropyrimidine dehydrogenase.

CT-179 is a potent and selective inhibitor of oligodendrocyte transcription factor 2 (OLIG2), reduces tumor cell proliferation and induces apoptosis, and enhances efficacy when used in combination with radiotherapy and other agents, showing potential in the treatment of medulloblastoma and glioblastoma.

3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3].

BSc5367 is a potent inhibitor of the structural domain of Nek1 kinase with an IC50=11.5 nM. Nek1 is a NIMA-associated protein kinase tightly linked to cell cycle regulation, DNA repair, and microtubule regulation. BSc5367 can be used in studies related to amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD), and several types of radiotherapy-resistant cancers.

Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy.

PROTACRIPK1Degrader-1 is a selective RIPK1 PROTAC degrader. This compound degrades RIPK1 in various cancer cell lines, such as A375 and B16F10 cells. It enhances the anticancer effects of radiotherapy in both syngeneic and humanized mouse models. PROTACRIPK1Degrader-1 is applicable for research in cancers like melanoma.

LCB-2151 (Compound 2) is a nucleoside analog and an anticancer agent. It disrupts the two main sources of ATP production, glycolysis and mitochondrial oxidative phosphorylation, reducing the bioenergetic capacity of KRAS mutant pancreatic cancer cells and inducing the formation of ROS. LCB-2151 effectively inhibits key enzymes in glycolysis, the TCA cycle, and fatty acid β-oxidation, such as CACT and CPT2. It demonstrates significant cytotoxicity and can induce apoptosis. LCB-2151 is applicable in cancer radiotherapy research.

NIMUSTINE, an antineoplastic agent especially effective against malignant brain tumors, has been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.

TDP1-IN-4 (Compound 33) is an inhibitor of tyrosyl-DNA phosphodiesterase 1 (TDP1) with an IC50 of 0.90 μM. It demonstrates strong synergistic effects with Camptothecin in SK-Mel-2 cells, but not in cancer cells (A549, HCT-116, and MCF-7 cells) or non-cancerous Ges-1 cells. TDP1-IN-4 is applicable in cancer chemotherapy and radiotherapy research.

CHK1-IN-14 is a free base form of a CHK1 inhibitor. It is utilized in research focused on resistance to chemotherapy and radiotherapy.

Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.

Dolasetron Mesylate hydrate (Dalasetron Mesylate Hydrate) , a selective serotonin receptor antagonist, competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.

BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative. BMS-599626 is an orally available and selective dual inhibitor of HER1 and HER2 with IC50s of 20 and 30 nM, respectively. BMS-599626 inhibits tumor cell proliferation and has the potential to increase tumor BMS-599626 inhibits tumor cell proliferation and has the potential to increase tumor response to radiotherapy.

CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E

L-778123 is an inhibitor of FPTase and GGPTase-I. The combination of L-778123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer.

GLYN, a nitric oxide donor, acts by enhancing the therapeutic efficacy of chemotherapy and radiotherapy.

NLCQ-1 is a novel weak DNA-intercalative bioreductive compound. NLCQ-1 exhibited a C50 of 44 microM. NLCQ-1 demonstrated significant hypoxic selectivity in several rodent (V79, EMT6, SCCVII) or human (A549, OVCAR-3) tumor cell lines. Its potency as a hypo

1. β,β-Dimethylacrylshikonin (Dimethylacrylshikonin) is a promising agent for developing an improved strategy for radiotherapy against tumors. (a) Injection of Dimethylacrylshikonin combined with IR treatment significantly suppressed tumor growth of the HCT-116 xenograft. (b) Dimethylacrylshikonin significantly suppressed the growth of H(22) transplantable hepatoma, and induced the activation of caspase-3 . (c) Dimethylacrylshikonin inhibited growth of gastric cancer SGC-791 cells by inducing ERK signaling pathway. 2. Dimethylacrylshikonin inhibits the proliferation of MCF-7 cells in vitro by inducing apoptosis through the downregulation of Bcl-2, upregulation of Bax and partial inactivation of the NF-κB pathway.

DNA-PK-IN-6, a robust DNA-PK inhibitor, effectively hampers the activity of DNA-PKcs, thereby significantly impairing the DNA repair mechanism in tumors and instigating apoptosis in cells. Additionally, DNA-PK-IN-6 amplifies the responsiveness of tumor tissues to radiotherapy, overcomes the challenge of drug resistance, and augments its inhibitory impact on a diverse range of solid and hematological tumors[1].

DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK that exerts a synergistic effect with radiotherapy and chemotherapy, enhancing therapeutic outcomes and significantly inhibiting tumor growth. Additionally, it demonstrates remarkable efficacy in reducing damage to normal cells, thereby minimizing adverse side effects, making it a compound of great potential for cancer research applications[1].

DNA-PK-IN-5 is a potent inhibitor of DNA-PK that inhibits DNA-PKcs activity, significantly reduces tumor DNA repair, and induces apoptosis. It enhances tumor tissue sensitivity to radiotherapy, overcomes drug resistance issues, and improves the inhibition of various solid and haematological tumors.

GPI-15427 is a potent PARP-1 inhibitor capable of crossing the blood-brain barrier, which can significantly increased the antitumor activity of the methylating agent TMZ against malignant melanoma, glioblastoma multiforme, or lymphoma growing at the CNS site. GPI-15427 acts as a potent inhibitor of the enzyme, being capable of inhibiting the activity of purified PARP-1 at nanomolar concentrations. GPI-15427 induced significant sensitization to radiotherapy, representing a promising new treatment in the management of HNSCC.

L-778123 is an inhibitor of FPTase and GGPTase-I, which was developed in part because it can completely inhibit Ki-Ras prenylation. The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed.

Dc-y13-27, a derivative of DC-Y13, is a potent YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 has antitumor activity that enhances the response of radiotherapy and immunotherapy to tumors.